Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer

Launched by SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE'S HOSPITAL · Sep 21, 2022

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment approach for women with locally advanced cervical cancer that cannot be surgically removed. The researchers want to see if combining neoadjuvant chemotherapy (which is treatment given before surgery) with a PD-1 antibody (a type of immunotherapy) and radical radiotherapy (high-dose radiation therapy) can help shrink the cancer before the standard treatment. This approach aims to reduce the size of the tumor, making it easier to treat later and potentially leading to fewer side effects from radiation.

To participate in this study, women aged 18 to 75 who have been diagnosed with cervical squamous cell carcinoma and whose cancer cannot be removed by surgery may be eligible. However, those with active autoimmune diseases will not be included in the trial. Participants can expect to receive the combination treatment and will be monitored for both the effectiveness of the treatment and any side effects that may arise. Overall, this study hopes to provide valuable information on how to better treat locally advanced cervical cancer in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patients who were pathologically diagnosed with cervical squamous cell carcinoma and were assessed as unresectable.
• Exclusion Criteria:
• • Any active or present autoimmune disease (eg, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism)